WE ARE BACKKKK. Get ready for the next #TxIDChat -- on Wednesday, Jan 21st at 730PM EST.
We are excited to announce with co-hosts @Mayyadah_HA and @ZYetmar and several surprise guests on the topic of Maximizing your One Year #TxID Fellowship!
Look forward to seeing you there!
Absolutely thankful for the support through the Kass Award @IDSA & @CCF_IMCHIEFS, most esp mentorship by one of the greatest ID staff I’ve ever come to work with @ZYetmar ! 🦠🥸
Happy 4️⃣ 🗓️ of July! Happy Independence Day, USA!🗽
Observe by expressing you opinion!
In this case, a follow-up survey on the transplant 🆔 library https://t.co/BOMS6dj5fu?
💯 % anonymous
🕑 <10 minutes!
Approved @AST_IDCOP and @EinsteinMed IRB
https://t.co/BQ60JgdrEw
I’m happy to share that our paper “Surgical Site Infection After Intestine Transplantation: Risk Factors & Outcomes” is now published
Grateful to everyone who contributed to this project and especially to Dr.Yetmar for his invaluable mentorship
https://t.co/5zKFgch5sT @ZYetmar
Do you use https://t.co/BOMS6dj5fu for #TxID?
Do you have ideas about improving it?
Do you prefer other resources? PubMed, texts, Google Scholar?
Tell us!
⌛ Anonymous survey <10 min⌛
Approved by @AST_IDCOP & @EinsteinMed IRB.
https://t.co/7J4MIhI5gy
Publication Alert
As we enter spring and warmer season, this is a reminder that tick-borne infections will soon be upon us.
Here is new data on human anaplasmosis: trends over a decade
@atiplis@omarabusaleh15@S_chesdachai@ZYetmar
https://t.co/HjMfdRKbrz
Optimal vaccination is challenging - especially in ICH pts!
New @NEJM@victoriahall26 study assessing flu vax in heme pts: two-dose adjuvanted v standard
💉 Similar seroconversion
💉 Better response in MM, though similar between arms
Find it in vax 📁!
https://t.co/oHOv4lNl8s
🆕 Review of MCS infections @IDClinics@emilymeich@StephaniePouch
❤️🔥 PET-CT helpful
❤️🔥 BSI ≥72h, MDROs, Candida can indicate device-specific inf
❤️🔥 Complicated inf may need suppression
Must-read for those new to LVADs!
Added to LVAD 📁 by @belga_sara
https://t.co/ciYWoi2iNo
Maribavir v. GCV - Resistance!
Subanalysis of pivotal maribavir trial @JIDJournal
Resistance:
💊More common w/ maribavir (10% v 2.5%)
💊Associated with VL ≥9100 IU/mL and refractory inf
In R/R CMV w/ high VL, do you start with maribavir?
Now in CMV 📁
https://t.co/UV5jyewyMQ